Epigenomics AG to Discover Biomarkers in R&D Collaboration with Centocor Inc.

Epigenomics AG (Frankfurt, Prime Standard: ECX) has entered into an R&D collaboration with Centocor Inc., a US-based, biomedicines company, to identify and analyze potential biomarkers for use in Centocor’s oncology program. Under the agreement, Epigenomics will use its proprietary Differential Methylation Hybridization (DMH) microarray platform to perform genome-wide DNA methylation profiling study on samples provided by Centocor.

Source: Epigenomics